Ernexa Therapeutics Inc. · NASDAQ:ERNA
Ernexa Therapeutics — Brooklyn ImmunoTherapeutics — Investor Presentation (September 2021)
9 slides from Ernexa Therapeutics's investor presentation, Sep 9, 2021
Slide 1: mRNA Engineered Cell & Cytokine Medicines
September 2021 mRNA Engineered Cell & Cytokine Medicines A platform company in cell, gene-editing & cytokine therapies
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide summary information about the business of Brooklyn ImmunoTherapeutics, Inc. (“BTX”). The information in this presentation is in no respects complete, comprehensive or exhaustive, and it should be read in conjunction with BTX’s public filings with t
Slide 3: BTX: World's Only mRNA Cell-Engineering Platform
BTX: World’s Only mRNA Cell-Engineering Platform What is mRNA cell-engineering? Messenger RNA (“mRNA”) is a special class of molecules that contain the instructions that determine how cells function. BTX’s platform is being designed to harness mRNA to engineer cells to treat disease by repairing dis
Slide 4: BTX: Leveraging In-licensed Patent Portfolio to Advance Medicine
BTX: Leveraging In-licensed Patent Portfolio to Advance Medicine BTX has an exclusive license from Factor Bioscience to a portfolio of granted patents around mRNA-based cell engineering that will provide BTX with a competitive advantageBTX’s major platform components:mRNA Cell Reprogramming (25 pate
Slide 5: Fields of Medicine Addressable with BTX Technology
Fields of Medicine Addressable with BTX Technology 5
Slide 6: ToRNAdo Delivery Offers Superior Results
ToRNAdo™ Delivery Offers Superior Results 6 Vector toxicity
Slide 7: An Investment in BTX Today Offers Future Value
An Investment in BTX Today Offers Future Value Breadth and depth of BTX technology offer numerous opportunities for successful clinical resultsBTX in-licensed patent portfolio offers potential for licensing and royalty revenue in coming yearsBTX technology platform offers predictable path to clinica
Slide 8: BTX Technology: Competitive Landscape
8 8 BTX CRISPR1 TALENs2 Zinc-Finger Nucleases3 mRNA Vaccines4 CAR-T5 Primary Technologies mRNA Cell ReprogrammingmRNA Gene EditingNoveSlice™ToRNAdo™ CRISPR(including base-editing) TALENs Zinc-Finger Nucleases None Viral Vectors for CAR-T mRNA Gene Editing Yes No No No No No mRNA Cell Reprogramming Y
Slide 9: mRNA Engineered Cell & Cytokine Medicines
September 2021 A platform company in cell, gene-editing & cytokine therapies mRNA Engineered Cell & Cytokine Medicines
Brooklyn ImmunoTherapeutics — Investor Presentation (September 2021) on 6ix